Theriva Biologics files $2.9M at-the-market equity offering through A.G.P.

Theriva Biologics, Inc.

Company filed a prospectus supplement for up to $2,894,225 of common stock in an ATM offering.
Sales agent is A.G.P./Alliance Global Partners; commission rate up to 3.0% of gross sales price.
Shares offered under existing effective S-3 registration statement (File No. 333-279077).
No arrangement for funds to be received in escrow; sales at market prices via commercial efforts.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.